HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. [electronic resource]
Producer: 20050721Description: 2252-60 p. digitalISSN:- 0008-543X
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Cyclophosphamide -- administration & dosage
- Docetaxel
- Doxorubicin -- administration & dosage
- Female
- Humans
- Ki-67 Antigen -- metabolism
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Invasiveness -- pathology
- Neoplasm Staging
- Prognosis
- Receptor, ErbB-2 -- metabolism
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Survival Rate
- Taxoids -- administration & dosage
- Tumor Suppressor Protein p53 -- metabolism
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.